Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies-Reference-Cited by-同舟云学术

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies

Published:2020-05-02 Issue:8 Volume:147 Page:2190-2198
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Piha‐Paul Sarina A.¹^ORCID,Oh Do‐Youn²,Ueno Makoto³,Malka David⁴,Chung Hyun Cheol⁵,Nagrial Adnan⁶,Kelley Robin K.⁷,Ros Willeke⁸,Italiano Antoine⁹^ORCID,Nakagawa Kazuhiko¹⁰,Rugo Hope S.¹¹,Braud Filippo¹²,Varga Andrea Iolanda¹³,Hansen Aaron¹⁴,Wang Hui¹⁵,Krishnan Suba¹⁶,Norwood Kevin G.¹⁶,Doi Toshihiko¹⁷

Affiliation:

1. Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of Internal Medicine Seoul National University Hospital, and Cancer Research Institute, Seoul National University College of Medicine Seoul Republic of Korea

3. Department of Gastroenterology Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center Yokohama Japan

4. Département de Médecine Oncologique Gustave Roussy, Université Paris‐Saclay Villejuif France

5. Department of Medical Oncology, Yonsei Cancer Center Yonsei University College of Medicine Seoul Republic of Korea

6. Blacktown Cancer and Haematology Centre Blacktown Hospital and University of Sydney Sydney New South Wales Australia

7. Division of Hematology/Oncology University of California San Francisco San Francisco California USA

8. Division of Pharmacology Antoni van Leeuwenhoek Ziekenhuis Amsterdam Netherlands

9. Early phase Trials and Sarcoma Units Institut Bergonié Bordeaux France

10. Department of Medical Oncology Kindai University Hospital Osaka Japan

11. Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco California USA

12. Department of Oncology and Hemato‐Oncology University of Milan and Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Tumori Milan Italy

13. Department of Drug Development Gustave Roussy, Université Paris‐Saclay Villejuif France

14. Division of Medical Oncology Princess Margaret Cancer Centre Toronto Ontario Canada

15. Biostatistical and Research Decision Sciences, Merck & Co., Inc. Kenilworth New Jersey USA

16. Oncology Late Development, Merck & Co., Inc. Kenilworth New Jersey USA

17. Department of Experimental Therapeutics/Gastrointestinal Oncology National Cancer Center Hospital East Kashiwa Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33013

Reference25 articles.

1. New Horizons for Precision Medicine in Biliary Tract Cancers

2. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

3. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Hepatobiliary Cancers Version 1.2019. Available at:https://www.nccn.org. Accessed February 22 2019.

5. Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

Cited by 288 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer;International Immunopharmacology;2024-03

2. Case report: From palliative to potentially curative – the advent of immunotherapy providing hope to advanced gallbladder adenocarcinoma;Frontiers in Immunology;2024-02-02

3. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome;Modern Pathology;2024-02

4. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma;BMC Medicine;2024-01-29

5. Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice;Frontiers in Immunology;2024-01-15